A genetic interaction analysis identifies cancer drivers that modify EGFR dependency.

Area of Science:

• Oncology
• Cancer Genomics
• Molecular Biology

Background:

• Numerous cancer driver genes identified via tumor sequencing.
• Limited understanding of genetic interactions and functional redundancy among cancer drivers.
• Epidermal growth factor receptor (EGFR) signaling is a key target in cancer therapy, particularly in non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To systematically investigate genetic interactions and functional redundancy among cancer drivers.
• To identify modifiers of epidermal growth factor receptor (EGFR) dependency in NSCLC.
• To explore the roles of tumor suppressor genes (TSGs) and oncogenes (OGs) in EGFR signaling pathways.

Main Methods:

• CRISPR screens
• shRNA screens
• Expression screens
• Utilized a non-small cell lung cancer (NSCLC) model

Main Results:

• Identified a wide range of TSGs and OGs that genetically modify cancer cell proliferation and survival under altered EGFR signaling.
• Discovered novel TSGs not previously linked to EGFR signaling.
• Demonstrated that mutations in PBRM1 attenuate EGFR inhibition by sustaining AKT signaling.
• Showed that mutations in CIC suppress EGFR inhibition effects by restoring EGFR-promoted gene expression, including Ets transcription factors like ETV1.

Conclusions:

• Many cancer drivers exhibit functional redundancy and can substitute for each other in specific contexts.
• The study broadens the understanding of EGFR regulation and identifies new potential therapeutic targets.
• Findings highlight the complex genetic landscape influencing EGFR inhibitor efficacy and resistance.